Diagnosis of Exercise-induced Bronchospasm (EIB) and Asthma in National Collegiate Athletic Association (NCAA) Division I Athletes
|ClinicalTrials.gov Identifier: NCT00752167|
Recruitment Status : Completed
First Posted : September 15, 2008
Last Update Posted : May 12, 2016
|Condition or disease|
|Exercise Induced Bronchospasm, Asthma|
Hide Detailed Description
We plan to identify all Division I athletes, male and female, at the University of Arizona that are currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff. In addition, athletes that were prescribed inhalers through Campus Health Services will be identified through review of electronic pharmacy records. Each athlete identified will be matched with two control athletes (ie, not currently using asthma medications) from the same sport. Subjects will be tested for EIB using eucapnic voluntary hyperventilation, the gold standard for making this diagnosis.
Subject Recruitment Potential subjects will be identified as described above. Subjects will be approached by one of the co-investigators, the study explained and an opportunity to review the consent form and ask question provided. Subjects who consent will then be scheduled for testing.
Questionnaire Subjects, once enrolled, will be asked to complete a 27 item questionnaire including questions about prior history and treatment of asthma, as well as history of respiratory symptoms. In addition, subjects will be asked to complete the Asthma Control Test (ACT).
EVH and Spirometric Testing All subjects will undergo baseline assessment of lung function using the KoKo Legend Portable Spirometer. The subjects will then undergo eucapnic voluntary hyperventilation testing. EVH testing will require the subject to hyperventilate dry air containing 5% carbon dioxide at room temperature for six minutes at a target ventilation of 30 times the subject's forced expiratory volume in one second (FEV1). The EVH test will be considered positive if a fall in FEV1 of 10% or more from baseline is recorded after a 6 minute period of hyperpnea. To overcome the problem of any post-test respiratory muscle fatigue, the FEV1 will be recorded at least three minutes after challenge and then repeated at three-minute intervals through 21 minutes.
Spirometry will be carried out according to American Thoracic Society standards. Both absolute and percent-predicted spirometric values will be recorded. Predicted values will be calculated from validated, published, race-specific regression equations. (Hankinson, et al. Spirometric reference values values from a sample of the general US population. Am J Respir Crit Care Med 1999; 159:179-187.) Asian-American athletes will be evaluated using norms for whites.
To provide the optimal test circumstances, some medications will be withheld for 8 to 96 hours before the bronchial provocation test: no short-acting bronchodilators, sodium cromoglycate, nedocromil sodium, or ipratropium bromide for 8 hours; no long-acting bronchodilators or antihistamines for 48 hours; no leukotriene antagonists for four days. Steroids should not be inhaled on the day of the test. No caffeine should be taken on the morning of the test. Vigorous exercise will be avoided for at least four hours prior to the start of the test as well as any exercise on the day of testing. Subjects will be scheduled for testing to allow at least 6-8 hours to elapse between previous vigorous activity and testing.
Exhaled Nitric Oxide (eNO) Measurement
Measurement of eNO will be obtained prior to measurement of pre-EVH spirometry. Exhaled NO will be measured employing a technique modified after Silkoff et al (1997) and following American Thoracic Society guidelines for eNO assessment (American Thoracic Society, 1999). In brief, this technique utilizes a resistive device that provides a constant low expiratory flow rate and ensures vellum closure. The combination of vellum closure and low flow rates, specifically 50 ml/s, assures accurate measurement of specific pulmonary derived eNO, while excluding potential contamination by nasal and paranasal sinuses NO (which can be a large source of eNO). Nitric oxide concentrations will be measured using a rapid-response chemiluminescent analyzer (NIOX™ System, Aerocrine, Sweden), which has a response time of < 700 ms for 10-90% full scale. The Food and Drug Administration has approved this device for clinical application in asthma management. The measurement circuit will consist of a mouthpiece-filter connected to a resistor/flow meter and collection bag. The participant will inhale to total lung capacity (TLC), insert the mouthpiece, and then immediately exhale slowly. During expiration, the participant will attempt to maintain a target flow of 50 ml/sec. The target period of exhalation time will be 10 seconds. However, for participants that are not able to perform the 10 second exhalation, the time requirements may be decreased to 6 seconds. Dietary history by recall for the 4-6 hours prior to testing will be obtained to screen for dietary sources of NO.
Data Collection Spirometric values and quality control measures for EVH testing will be recorded on forms specifically designed for this purpose and, for spirometry, already in use in the Pediatric Pulmonary Function Laboratory. Data will entered into a computer spreadsheet and double-checked by a second person to assure accuracy. It will then be transferred to a statistical package (STATA) for subsequent analysis.
Data Analysis For this observational study summative and descriptive statistics will be carried out. If opportunities for comparative analysis are identified, parametric and nonparametric analysis will be carried out as appropriate.
A fall occurring early in the post-EVH period, especially in conjunction with documented pre-exercise elevation in eNO, will be taken as being more suggestive of poorly controlled asthma, while a fall 9-12 minutes after EVH, especially in the absence of an elevated eNO, will be interpreted as being more indicative of true EIB.
|Study Type :||Observational|
|Actual Enrollment :||74 participants|
|Observational Model:||Case Control|
|Official Title:||Diagnosis of EIB and Asthma in NCAA Division I Athletes|
|Study Start Date :||February 2007|
|Actual Primary Completion Date :||June 2008|
|Actual Study Completion Date :||June 2008|
all Division I athletes, male and female, at the University of Arizona that are currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff
control athletes (ie, not currently being treated for either EIB or asthma by review of preparticipation physical forms or identified by the medical staff and/or not currently using asthma medications) from the same sport
- Change in FEV1 following eucapnic voluntary hyperventilation [ Time Frame: 3-21 minutes ]
- Protection from fall in FEV1 following eucapnic voluntary hyperventilation by preadministration of albuterol [ Time Frame: 3-21 minutes ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00752167
|United States, Arizona|
|University of Arizona|
|Tucson, Arizona, United States, 85724|
|Principal Investigator:||David Millward, MD||University of Arizona|